재조합 백신 시장 : 적응증별(인유두종 바이러스, 수막염균, 기타), 최종 사용자별(소아, 성인), 유통 채널별(병원, 예방 접종 센터) - 세계 기회 분석 및 산업 예측(2021-2031년)

The global recombinant vaccines market was valued at $8,080.37 million in 2021, and is projected to reach $24,698.79 million by 2031, registering a CAGR of 11.4% from 2022 to 2031.

A recombinant vaccine is a vaccine produced through recombinant DNA technology. This involves inserting the DNA encoding an antigen (such as a bacterial surface protein) that stimulates an immune response into bacterial or mammalian cells, expressing the antigen in these cells and then purifying it from them. It is expressed as DNA, proteins and live vaccines. The DNA version is cheaper to make and is thermostable, which does not require the "cold chain" for transportation and preservation. A large number of studies have been done on development of DNA vaccines. However, a few DNA vaccines have succeeded in becoming DNA vaccines for human use. The live recombinant vaccines are made of a live viral or bacterial vector that was engineered to express a variety of exogenous antigens in the cytoplasm of target cells, in this case HIV-1 or genes.

The growth of the recombinant vaccines market is driven by increase in research and development activities for recombinant vaccines, rise in the prevalence of infectious diseases and increase in rates of vaccinations globally. Moreover, increasing incidence of zoonotic diseases, emerging technologies for developing vaccines and rise in the number of product approvals also helps in the growth of the market. For instance, in June 2021, Merck and Sanofi received an approval for six-in-one pediatric combination vaccine in the U.S. However, prolong period for introduction of new vaccines is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.

The global recombinant vaccines market is segmented based on indication, end user, distribution channel and region. On the basis of indication, the market is bifurcated into human papillomavirus, meningococcal and others. On the basis of end user, the market is classified into pediatric and adult. On the basis of distribution channel, the market is classified into hospitals and vaccination centers. The hospitals segment is further subsegment on the basis of type into private and public. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key market players operating in this market include, AstraZeneca Plc., Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the recombinant vaccines market analysis from 2021 to 2031 to identify the prevailing recombinant vaccines market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the recombinant vaccines market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global recombinant vaccines market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

• Human Papillomavirus
• Meningococcal
• Others

By End User

• Pediatric
• Adults

By Distribution Channel

• Hospitals
  • Type
  • Private
  • Public
• Vaccination Centers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
• Key Market Players
  • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: RECOMBINANT VACCINES MARKET, BY INDICATION

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Human Papillomavirus
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Meningococcal
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country
• 4.4 Others
  • 4.4.1 Key market trends, growth factors and opportunities
  • 4.4.2 Market size and forecast, by region
  • 4.4.3 Market analysis by country

CHAPTER 5: RECOMBINANT VACCINES MARKET, BY END USER

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Pediatric
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Adults
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country

CHAPTER 6: RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospitals
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
  • 6.2.4 Hospitals Recombinant Vaccines Market by Type
    • 6.2.4.1 Private Market size and forecast, by region
    • 6.2.4.2 Public Market size and forecast, by region
• 6.3 Vaccination Centers
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country

CHAPTER 7: RECOMBINANT VACCINES MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Indication
  • 7.2.3 North America Market size and forecast, by End User
  • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.4.1 North America Hospitals Recombinant Vaccines Market by Type
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Indication
    • 7.2.5.1.2 Market size and forecast, by End User
    • 7.2.5.1.3 Market size and forecast, by Distribution Channel
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Indication
    • 7.2.5.2.2 Market size and forecast, by End User
    • 7.2.5.2.3 Market size and forecast, by Distribution Channel
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Indication
    • 7.2.5.3.2 Market size and forecast, by End User
    • 7.2.5.3.3 Market size and forecast, by Distribution Channel
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Indication
  • 7.3.3 Europe Market size and forecast, by End User
  • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.4.1 Europe Hospitals Recombinant Vaccines Market by Type
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Indication
    • 7.3.5.1.2 Market size and forecast, by End User
    • 7.3.5.1.3 Market size and forecast, by Distribution Channel
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Indication
    • 7.3.5.2.2 Market size and forecast, by End User
    • 7.3.5.2.3 Market size and forecast, by Distribution Channel
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Indication
    • 7.3.5.3.2 Market size and forecast, by End User
    • 7.3.5.3.3 Market size and forecast, by Distribution Channel
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Indication
    • 7.3.5.4.2 Market size and forecast, by End User
    • 7.3.5.4.3 Market size and forecast, by Distribution Channel
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Indication
    • 7.3.5.5.2 Market size and forecast, by End User
    • 7.3.5.5.3 Market size and forecast, by Distribution Channel
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Indication
    • 7.3.5.6.2 Market size and forecast, by End User
    • 7.3.5.6.3 Market size and forecast, by Distribution Channel
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Indication
  • 7.4.3 Asia-Pacific Market size and forecast, by End User
  • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.4.1 Asia-Pacific Hospitals Recombinant Vaccines Market by Type
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Indication
    • 7.4.5.1.2 Market size and forecast, by End User
    • 7.4.5.1.3 Market size and forecast, by Distribution Channel
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Indication
    • 7.4.5.2.2 Market size and forecast, by End User
    • 7.4.5.2.3 Market size and forecast, by Distribution Channel
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Market size and forecast, by Indication
    • 7.4.5.3.2 Market size and forecast, by End User
    • 7.4.5.3.3 Market size and forecast, by Distribution Channel
    • 7.4.5.4 India
    • 7.4.5.4.1 Market size and forecast, by Indication
    • 7.4.5.4.2 Market size and forecast, by End User
    • 7.4.5.4.3 Market size and forecast, by Distribution Channel
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Indication
    • 7.4.5.5.2 Market size and forecast, by End User
    • 7.4.5.5.3 Market size and forecast, by Distribution Channel
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Indication
    • 7.4.5.6.2 Market size and forecast, by End User
    • 7.4.5.6.3 Market size and forecast, by Distribution Channel
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Indication
  • 7.5.3 LAMEA Market size and forecast, by End User
  • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.4.1 LAMEA Hospitals Recombinant Vaccines Market by Type
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Indication
    • 7.5.5.1.2 Market size and forecast, by End User
    • 7.5.5.1.3 Market size and forecast, by Distribution Channel
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Indication
    • 7.5.5.2.2 Market size and forecast, by End User
    • 7.5.5.2.3 Market size and forecast, by Distribution Channel
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Indication
    • 7.5.5.3.2 Market size and forecast, by End User
    • 7.5.5.3.3 Market size and forecast, by Distribution Channel
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Indication
    • 7.5.5.4.2 Market size and forecast, by End User
    • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 Pfizer Inc.
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments